Evidence map›Paper›PMID 27354766›Full record

ArticleDrug design, development and therapy2016

The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma.

Hatem A Sarhan, Omar H El-Garhy, Mohamed A Ali, Nouran A Youssef

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04929626 (Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04929626 phase1completednot on this mapstarted 2022, after this paper: background citation

Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus

TypeinterventionalSponsorZiauddin UniversityRan2022 to 2022Enrolled126ConditionsStatus AsthmaticusArmsMagnesium Sulfate 500 mg/ml+ ventolin, Ventolin
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Inhaled magnesium sulfate in the treatment of acute asthma.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Review
  3. Effectiveness of Intravenous and Nebulized MgSOChildren (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Review
  6. Salbutamol in the Management of Asthma: A Review.International journal of molecular sciences · 2022
    Review
  7. The relevance of magnesium homeostasis in COVID-19.European journal of nutrition · 2022
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hatem A SarhanDepartment of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Omar H El-GarhyDepartment of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Mohamed A AliDepartment of Chest Diseases, Faculty of Medicine, Minia University, Minia, Egypt.
Nouran A YoussefDepartment of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Minia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma.

methodsA double-blind randomized controlled study was conducted in Chest and Emergency Departments. Thirty patients of acute attack of bronchial asthma were randomized into three groups: MgSO4 nebulization (group A), salbutamol nebulization (group B), and their combination (group C). All patients were monitored before and after nebulization (each 20 minutes) for peak expiratory flow rate (PEFR), respiratory rate (RR), heart rate (HR), blood pressure, pulsus paradoxus, oxygen saturation, clinical examination, and Fischl index.

resultsA highly significant improvement in PEFR, PEFR percentage, and Fischl index and significant decrease in RR and HR was observed in all groups. A similar improvement in PEFR was observed in group A and group B (P=0.389). The difference in peak expiratory flow (PEF) improvement was insignificant between group B and group C (P=0.101), while there was a significant difference between group A and group C (P=0.014) in favor of group C.

conclusionNebulized MgSO4 alone or combined with salbutamol has a clinically significant bronchodilator effect in acute asthma and leads to clinical improvement, increase in PEFR, reduction in HR, and reduction in RR. The response to nebulized MgSO4 alone (PEFR improvement 54±35.6 L/min, P=0.001) is comparable (P=0.389) to that of nebulized salbutamol (PEFR improvement 67.0±41.9 L/min, P=0.001) and is significantly less than (P=0.014) that of nebulized combination (PEFR improvement 92.0±26.9 L/min, P=0.000).

Indexed as

Acute DiseaseAdministration, InhalationAirway ObstructionAlbuterolAsthmaDouble-Blind MethodHumansMagnesium SulfatePeak Expiratory Flow RateAlbuterolMagnesium Sulfateacute asthmaFischl indexnebulized magnesium sulfatepeak expiratory flow ratesalbutamol

Identifiers

PMID27354766
PMCPMC4907636
OpenAlexW2413059647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.